The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

Globe Investor

News Sources

Take control of your investments with the latest investing news and analysis

Press release from PR Newswire

Cardinal Health Reports Fiscal 2013 First-Quarter Results

Tuesday, October 30, 2012

Cardinal Health Reports Fiscal 2013 First-Quarter Results07:00 EDT Tuesday, October 30, 2012- Operating earnings increase 11 percent to $457 million, or 6 percent to $469 million on a non-GAAP basis(1) - Diluted earnings per share from continuing operations increase 16 percent to $0.79, or 11 percent to $0.81 on a non-GAAP basis - Board of directors approves further 16 percent dividend increaseDUBLIN, Ohio, Oct. 30, 2012 /PRNewswire/ -- Cardinal Health today reported fiscal year 2013 first-quarter revenue of $25.9 billion and an 11 percent increase in non-GAAP diluted earnings per share (EPS) from continuing operations to $0.81.In addition, the company reaffirmed its fiscal 2013 outlook for non-GAAP diluted EPS from continuing operations of $3.35 to $3.50.  "We were pleased to report a solid beginning to our fiscal 2013. As we had expected, revenue was down, as a result of the pharmaceutical industry's wave of brand-to-generic conversions.  Our margin expansion continued to be strong, led by our Pharmaceutical segment and fueled by excellent contribution from our generic programs," said George Barrett, chairman and chief executive officer of Cardinal Health. "Our Medical segment started the year more slowly than we planned, largely due to lighter than expected procedure volumes and some continued operational cleanup of our major systems and process transformation. We continue to target double digit segment profit growth for our Medical segment for fiscal year 2013."The just-announced decision to increase the dividend by another 16 percent underscores our commitment to a differentiated dividend. This adds to the 10.5 percent increase realized in July, bringing our anticipated annualized payout ratio to over 30 percent of our fiscal 2013 outlook for non-GAAP EPS. Combined with the $200 million in share repurchases completed year-to-date in fiscal 2013, these actions reinforce our commitment to returning capital to shareholders while driving the underlying growth in the business," he continued.Q1 FY13 SUMMARYQ1 FY13Q1 FY12Y/YRevenue$25.9 billion$26.8 billion(3%) Operating Earnings $457 million $412 million 11%Non-GAAP Operating Earnings $469 million $442 million 6%Earnings from Continuing Operations $272 million $237 million 15%Non-GAAP Earnings from Continuing Operations $281 million $256 million 9%Diluted EPS from Continuing Operations $0.79 $0.68 16%Non-GAAP Diluted EPS from Continuing Operations $0.81 $0.73 11%SEGMENT RESULTSPharmaceutical segmentAs expected, revenue for the Pharmaceutical segment declined 4 percent to $23.5 billion, driven primarily by brand-to-generic conversions, partially offset by sales to new customers within pharmaceutical distribution and higher specialty solutions volume.  Segment profit increased 10 percent to $400 million, with the growth primarily reflecting contribution from our generics programs.Q1 FY13Q1 FY12Y/YRevenue$23.5 billion$24.4 billion(4%)Segment Profit$400 million$363 million10%Medical segmentRevenue for the Medical segment was up 1 percent to $2.4 billion. Last year's acquisition of Futuremed and growth in our preferred products was partially offset by one fewer sales day and lower sales to existing customers due in part to lower-than-expected procedural volume in the hospital market. Segment profit declined 6 percent to $74 million primarily driven by the volume softness and the net impact of the information systems-related issues. Q1 FY13Q1 FY12Y/YRevenue$2.4 billion$2.4 billion1%Segment Profit$74 million$79 million(6%)ADDITIONAL FIRST-QUARTER AND RECENT HIGHLIGHTSElected Clayton M. Jones, chairman, president and CEO of Rockwell Collins, to board of directors. Launched evidence-based clinical pathways with Health Alliance Plan and Physician Resource Management to improve quality and curb cancer care costs for patients in Michigan. Launched ambulatory surgery center solution, Manage My ASC, to help surgical center owners and managers improve operational and financial performance. Introduced SecureSeal? Octyl Topical Skin Adhesive making the company's topical skin adhesive portfolio the most comprehensive in the market.   CONFERENCE CALLCardinal Health will host a webcast and conference call today at 8:30 a.m. Eastern time to discuss first-quarter results. To access the call and corresponding slide presentation, go to the Investors page at cardinalhealth.com. The call also can be accessed by dialing 224.357.2209. There is no access code for the call.  Presentation slides and an audio replay will be archived on the website after the conclusion of the meeting. The audio replay will also be available until Nov. 30 by dialing 855.859.2056 or 404.537.3406, access code 35940715.UPCOMING EVENTSAnnual Meeting of Shareholders at 8 a.m. local time on Nov. 2 at the company headquarters in Dublin, Ohio Credit Suisse Healthcare Conference at 8:30 a.m. local time on Nov. 14 at the Arizona Biltmore Hotel in Phoenix.At these events, Cardinal Health will discuss the company's diverse products and services, company performance and strategies for continued growth. To access more details and live webcasts of these events, go to the Investors page at cardinalhealth.com.  About Cardinal Health Headquartered in Dublin, Ohio, Cardinal Health, Inc. (NYSE: CAH) is a $108 billion health care services company that improves the cost-effectiveness of health care. As the business behind health care, Cardinal Health helps pharmacies, hospitals, ambulatory surgery centers and physician offices focus on patient care while  reducing costs, enhancing efficiency and improving quality. Cardinal Health is an essential link in the health care supply chain, providing pharmaceuticals and medical products to more than 60,000 locations each day. The company is also a leading manufacturer of medical and surgical products, including gloves, surgical apparel and fluid management products. In addition, the company supports the growing diagnostic industry by supplying medical products to clinical laboratories and operating the nation's largest network of radiopharmacies that dispense products to aid in the early diagnosis and treatment of disease. Ranked #21 on the Fortune 500, Cardinal Health employs more than 30,000 people worldwide. More information about the company may be found at cardinalhealth.com and @CardinalHealth on Twitter.1 See the attached tables for definitions of the non-GAAP financial measures presented in this news release and reconciliations of the differences between the non-GAAP financial measures and their most directly comparable GAAP financial measures.Cardinal Health uses its website as a channel of distribution for material company information. Important information, including news releases, analyst presentations and financial information regarding Cardinal Health is routinely posted and accessible on the Investors page at cardinalhealth.com.Cautions Concerning Forward-Looking StatementsThis news release contains forward-looking statements addressing expectations, prospects, estimates and other matters that are dependent upon future events or developments. These statements may be identified by words such as "expect," "anticipate," "intend," "plan," "believe," "will," "should," "could," "would," "project," "continue," "likely," and similar expressions, and include statements reflecting future results or guidance, statements of outlook and expense accruals. These matters are subject to risks and uncertainties that could cause actual results to differ materially from those projected, anticipated or implied. These risks and uncertainties include competitive pressures in Cardinal Health's various lines of business; the loss of one or more key customer or supplier relationships or changes to the terms of those relationships, including our relationships with CVS Caremark Corporation and Walgreen Co.; the timing of generic and branded pharmaceutical introductions and the frequency or rate of pharmaceutical price appreciation or deflation; uncertainties due to government health care reform including federal health care reform legislation; changes in the distribution patterns or reimbursement rates for health care products and services; the effects of any investigation or action by any regulatory authority; changes in the cost of commodities such as oil-based resins, cotton, latex and diesel fuel; uncertainties concerning Cardinal Health's ability to achieve the expected benefits of its Medical segment's business transformation project; and with respect to future dividends, the decision by Cardinal Health's board of directors to declare such dividends, which decision will depend on Cardinal Health's surplus, earnings, cash flows, financial condition and prospects at the time any such action is considered. Cardinal Health is subject to additional risks and uncertainties described in Cardinal Health's Form 10-K, Form 10-Q and Form 8-K reports and exhibits to those reports. This news release reflects management's views as of October 30, 2012. Except to the extent required by applicable law, Cardinal Health undertakes no obligation to update or revise any forward-looking statement.  Schedule 1Cardinal Health, Inc. and SubsidiariesCondensed Consolidated Statements of Earnings (Unaudited)First Quarter(in millions, except per Common Share amounts)20132012% ChangeRevenue$25,889$26,792(3)%Cost of products sold24,73025,708(4)%Gross margin1,1591,0847%Operating expenses:Distribution, selling, general and administrative expenses6906447%Restructuring and employee severance53N.M.Acquisition-related costs2827N.M.Impairments and loss on disposal of assets11N.M.Litigation (recoveries)/charges, net(22)(3)N.M.Operating earnings45741211%Other (income)/expense, net(8)4N.M.Interest expense, net262311%Earnings before income taxes and discontinued operations43938514%Provision for income taxes16714813%Earnings from continuing operations27223715%Loss from discontinued operations, net of tax(1)?N.M.Net earnings$271$23715%Basic earnings per Common Share:Continuing operations$0.80$0.6916%Discontinued operations??N.M.Net basic earnings per Common Share$0.80$0.6916%Diluted earnings per Common Share:Continuing operations$0.79$0.6816%Discontinued operations??N.M.Net diluted earnings per Common Share$0.79$0.6816%Weighted-average number of Common Shares outstanding:Basic341345Diluted344349 Schedule 2Cardinal Health, Inc. and SubsidiariesCondensed Consolidated Balance Sheets(in millions)September 30, 2012June 30, 2012(Unaudited)AssetsCurrent assets:Cash and equivalents$2,440$2,274Trade receivables, net6,4496,355Inventories8,1057,864Prepaid expenses and other1,0131,017Total current assets18,00717,510Property and equipment, net1,5111,551Goodwill and other intangibles, net4,4414,392Other assets861807Total assets$24,820$24,260Liabilities and Shareholders' EquityCurrent liabilities:Accounts payable$12,215$11,726Current portion of long-term obligations and other short-term borrowings471476Other accrued liabilities1,9831,972Total current liabilities14,66914,174Long-term obligations, less current portion2,4082,418Deferred income taxes and other liabilities1,4621,424Total shareholders' equity6,2816,244Total liabilities and shareholders' equity$24,820$24,260 Schedule 3Cardinal Health, Inc. and SubsidiariesCondensed Consolidated Statements of Cash Flows (Unaudited)First Quarter(in millions)20132012Cash flows from operating activities:Net earnings$271$237Loss from discontinued operations, net of tax1?Earnings from continuing operations272237Adjustments to reconcile earnings from continuing operations to net cash from operations:Depreciation and amortization8878Impairments and loss on disposal of assets11Share-based compensation2420Provision for bad debts11Change in operating assets and liabilities, net of effects from acquisitions:Increase in trade receivables(71)(69)Increase in inventories(207)(161)Increase in accounts payable464410Other accrued liabilities and operating items, net(4)(13)Net cash provided by operating activities568504Cash flows from investing activities:Acquisition of subsidiaries, net of cash acquired(100)(7)Additions to property and equipment(26)(45)Proceeds from maturities of held-to-maturity securities2310Net cash used in investing activities(103)(42)Cash flows from financing activities:Net change in short-term borrowings(10)(5)Reduction of long-term obligations(4)?Proceeds from issuance of Common Shares2118Tax disbursements from share-based compensation(22)(17)Dividends on Common Shares(84)(77)Purchase of treasury shares(200)(300)Net cash used in financing activities(299)(381)Net increase in cash and equivalents16681Cash and equivalents at beginning of period2,2741,930Cash and equivalents at end of period$2,440$2,011 Schedule 4Cardinal Health, Inc. and SubsidiariesTotal Company Business AnalysisNon-GAAPFirst QuarterFirst Quarter(in millions)2013201220132012RevenueAmount$25,889$26,792Growth rate(3)%10%Operating earningsAmount$457$412$469$442Growth rate11%13%6%16%Earnings from continuing operationsAmount$272$237$281$256Growth rate15%(19)%9%11%Refer to the GAAP/Non-GAAP reconciliation for definitions and calculations supporting the Non-GAAP balances. Schedule 5Cardinal Health, Inc. and SubsidiariesSegment Business AnalysisFirst QuarterFirst Quarter(in millions)20132012(in millions)20132012PharmaceuticalMedicalRevenueRevenueAmount$23,498$24,418Amount$2,393$2,380Growth rate(4)%10%Growth rate1%10%Mix91%91%Mix9%9%Segment profitSegment profitAmount$400$363Amount$74$79Growth rate10%19%Growth rate(6)%(5)%Mix84%82%Mix16%18%Segment profit margin1.70%1.49%Segment profit margin3.11%3.32%Refer to definitions for an explanation of calculations.Total consolidated revenue for the three months ended September 30, 2012 was $25,889 million, which included total segment revenue of $25,891 million and Corporate revenue of $(2) million. Total consolidated revenue for the three months ended September 30, 2011 was $26,792 million, which included total segment revenue of $26,798 million and Corporate revenue of $(6) million.  Corporate revenue consists primarily of elimination of inter-segment revenue.Total consolidated operating earnings for the three months ended September 30, 2012 were $457 million, which included total segment profit of $474 million and Corporate costs of $(17) million. Total consolidated operating earnings for the three months ended September 30, 2011 were $412 million, which included total segment profit of $442 million and Corporate costs of $(30) million. Corporate includes, among other things, restructuring and employee severance, acquisition-related costs, impairments and loss on disposal of assets, litigation (recoveries)/charges, net and certain investment spending that are not allocated to the segments. Schedule 6Cardinal Health, Inc. and SubsidiariesSchedule of Notable ItemsFirst Quarter(in millions, except per Common Share amounts)20132012Restructuring and employee severance$(5)$(3)Tax benefit21Restructuring and employee severance, net of tax$(3)$(2)Decrease to diluted EPS from continuing operations$(0.01)$(0.01)Acquisition-Related CostsAmortization of acquisition-related intangible assets$(21)$(19)Tax benefit86Amortization of acquisition-related intangible assets, net of tax$(13)$(13)Decrease to diluted EPS from continuing operations$(0.04)$(0.04)Other acquisition-related costs$(7)$(9)Tax benefit23Other acquisition-related costs, net of tax$(5)$(6)Decrease to diluted EPS from continuing operations$(0.01)$(0.02)Total acquisition-related costs1$(28)$(27)Tax benefit109Total acquisition-related costs, net of tax1$(18)$(18)Decrease to diluted EPS from continuing operations1$(0.05)$(0.05)Impairments and loss on disposal of assets$(1)$(1)Tax benefit??Impairments and loss on disposal of assets, net of tax$(1)$(1)Decrease to diluted EPS from continuing operations$?$?Litigation recoveries/(charges), net$22$3Tax expense(9)(1)Litigation recoveries/(charges), net, net of tax$13$2Increase to diluted EPS from continuing operations$0.04$0.01Other Spin-Off Costs$?$(1)Tax benefit?1Other Spin-Off Costs, net of tax$?$?Decrease to diluted EPS from continuing operations$?$?Weighted-average number of diluted shares outstanding3443491 The sum of the components may not equal the total due to rounding.We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred. Schedule 7Cardinal Health, Inc. and SubsidiariesAsset Management AnalysisFirst Quarter20132012Days sales outstanding122.420.9Days inventory on hand25.423.0Days payable outstanding38.336.1Net working capital days29.57.9Debt to total capital31%31%Net debt to capital7%8%Return on equity17.3%16.4%Non-GAAP return on equity17.9%17.7%Effective tax rate from continuing operations38.1%38.4%Non-GAAP effective tax rate from continuing operations37.8%38.1%1  We changed our method of calculating days sales outstanding and have revised prior year information to conform.2  The sum of the components may not equal the total due to rounding. Refer to the GAAP/Non-GAAP reconciliation for definitions and calculations supporting the Non-GAAP balances. Refer to DSO, DIOH and DPO for definitions and calculations. Schedule 8Cardinal Health, Inc. and SubsidiariesGAAP / Non-GAAP ReconciliationFirst Quarter 2013OperatingEarnings BeforeProvisionEarningsEarnings fromDiluted EPSDiluted EPSEarningsIncome TaxesforfromContinuingfromfrom Continuing(in millions, except perOperatingGrowthand DiscontinuedIncomeContinuingOperationsContinuingOperations  Common Share amounts)EarningsRateOperationsTaxesOperationsGrowth RateOperationsGrowth RateGAAP$45711%$439$167$27215%$0.7916%Restructuring and employee severance55230.01Acquisition-related costs282810180.05Impairments and loss on disposal of assets11?1?Litigation (recoveries)/charges, net(22)(22)(9)(13)(0.04)Other Spin-Off Costs?????Non-GAAP$4696%$451$170$2819%$0.8111%First Quarter 2012GAAP$41213%$385$148$237(19)%$0.68(19)%Restructuring and employee severance33120.01Acquisition-related costs27279180.05Impairments and loss on disposal of assets11?1?Litigation (recoveries)/charges, net(3)(3)(1)(2)(0.01)Other Spin-Off Costs111??Non-GAAP$44216%$414$158$25611%$0.7311%The sum of the components may not equal the total due to rounding.We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred. Schedule 9Cardinal Health, Inc. and SubsidiariesGAAP / Non-GAAP ReconciliationFirst Quarter(in millions)20132012GAAP return on equity17.3%16.4%Non-GAAP return on equityNet earnings$271$237Restructuring and employee severance, net of tax, in continuing operations32Acquisition-related costs, net of tax, in continuing operations1818Impairments and loss on disposal of assets, net of tax, in continuing operations11Litigation (recoveries)/charges, net, net of tax, in continuing operations(13)(2)Other Spin-Off Costs, net of tax, in continuing operations??Adjusted net earnings$280$256Annualized$1,120$1,024FirstFourthFirstFourthQuarterQuarterQuarterQuarter2013201220122011Total shareholders' equity$6,281$6,244$5,714$5,849Divided by average shareholders' equity$6,263$5,781Non-GAAP return on equity17.9%17.7%We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred. Schedule 10Cardinal Health, Inc. and SubsidiariesGAAP / Non-GAAP ReconciliationFirst Quarter(in millions)20132012GAAP effective tax rate from continuing operations38.1%38.4%Non-GAAP effective tax rate from continuing operationsEarnings before income taxes and discontinued operations$439$385Restructuring and employee severance53Acquisition-related costs2827Impairments and loss on disposal of assets11Litigation (recoveries)/charges, net(22)(3)Other Spin-Off Costs?1Adjusted earnings before income taxes and discontinued operations$451$414Provision for income taxes$167$148Restructuring and employee severance tax benefit21Acquisition-related costs tax benefit109Impairments and loss on disposal of assets tax benefit??Litigation (recoveries)/charges, net tax expense(9)(1)Other Spin-Off Costs tax benefit?1Adjusted provision for income taxes$170$158Non-GAAP effective tax rate from continuing operations37.8%38.1%First Quarter20132012Debt to total capital31%31%Net debt to capitalCurrent portion of long-term obligations and other short-term borrowings$471$333Long-term obligations, less current portion2,4082,195Debt$2,879$2,528Cash and equivalents(2,440)(2,011)Net debt$439$517Total shareholders' equity6,2815,714Capital$6,720$6,231Net debt to capital7%8%We apply varying tax rates depending on the item's nature and tax jurisdiction where it is incurred.Forward-Looking Non-GAAP Financial MeasuresWe present non-GAAP earnings from continuing operations and non-GAAP effective tax rate from continuing operations (and presentations derived from these financial measures, including per share calculations) on a forward-looking basis. The most directly comparable forward-looking GAAP measures are earnings from continuing operations and effective tax rate from continuing operations. We are unable to provide a quantitative reconciliation of these forward-looking non-GAAP measures to the most directly comparable forward-looking GAAP measures because we cannot reliably forecast restructuring and employee severance, acquisition-related costs, impairments and loss on disposal of assets, litigation (recoveries)/charges, net, and other spin-off costs, which are difficult to predict and estimate and are primarily dependent on future events. Please note that the unavailable reconciling items could significantly impact our future financial results. Schedule 11Cardinal Health, Inc. and SubsidiariesFirst Quarter(in millions)20132012Days sales outstanding22.420.9Days inventory on handInventories$8,105$7,497Cost of products sold$24,730$25,708Chargeback billings3,9763,610Adjusted cost of products sold$28,706$29,318Adjusted cost of products sold divided by 90 days$319$326Days inventory on hand25.423.0Days payable outstandingAccounts payable$12,215$11,749Cost of products sold$24,730$25,708Chargeback billings3,9763,610Adjusted cost of products sold$28,706$29,318Adjusted cost of products sold divided by 90 days$319$326Days payable outstanding38.336.1Net working capital days19.57.91    The sum of the components may not equal the total due to rounding. Days Sales Outstanding (DSO): trade receivables, net divided by (quarterly revenue divided by 90 days). Beginning in the first quarter of fiscal 2013, we changed our method of calculating DSO in order to align it with the 90-day convention that we use in the calculation of Days Inventory on Hand and Days Payable Outstanding. Prior to this change we calculated DSO by dividing trade receivable, net by (monthly revenue divided by 30 days). In connection with this change, we have revised prior year information to conform to the new method of calculating DSO. Days Inventory on Hand: inventory divided by ((quarterly cost of products sold plus chargeback billings) divided by 90 days). Chargeback billings are the difference between a product's wholesale acquisition cost and the contract price established between pharmaceutical manufacturers and the end customer.Days Payable Outstanding: accounts payable divided by ((quarterly cost of products sold plus chargeback billings) divided by 90 days).Net Working Capital Days: days sales outstanding plus days inventory on hand less days payable outstanding. To conform to the new method of calculating DSO, we have revised prior year information.  Cardinal Health, Inc. and SubsidiariesUse of Non-GAAP MeasuresThis earnings release contains financial measures that are not calculated in accordance with U.S. generally accepted accounting principles ("GAAP").  In general, the measures exclude items and charges that (i) management does not believe reflect Cardinal Health, Inc.'s (the "Company") core business and relate more to strategic, multi-year corporate activities; or (ii) relate to activities or actions that may have occurred over multiple or in prior periods without predictable trends.  Management uses these non-GAAP financial measures internally to evaluate the Company's performance, evaluate the balance sheet, engage in financial and operational planning and determine incentive compensation.Management provides these non-GAAP financial measures to investors as supplemental metrics to assist readers in assessing the effects of items and events on its financial and operating results and in comparing the Company's performance to that of its competitors.  However, the non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies.The non-GAAP financial measures disclosed by the Company should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP, and the financial results calculated in accordance with GAAP and reconciliations to those financial statements set forth above should be carefully evaluated.DefinitionsDebt: long-term obligations plus short-term borrowings.Debt to Total Capital: debt divided by (debt plus total shareholders' equity).Net Debt: a Non-GAAP measure defined as debt minus (cash and equivalents).Net Debt to Capital: a Non-GAAP measure defined as net debt divided by (net debt plus total shareholders' equity).Non-GAAP Diluted EPS from Continuing Operations and growth rate calculation1: non-GAAP earnings from continuing operations divided by diluted weighted-average shares outstanding.Non-GAAP Earnings from Continuing Operations and growth rate calculation: earnings from continuing operations excluding (1) restructuring and employee severance2, (2) acquisition-related costs3, (3) impairments and loss on disposal of assets4, (4) litigation (recoveries)/charges, net5 and (5) Other Spin-Off Costs, each net of tax.Non-GAAP Effective Tax Rate from Continuing Operations: (provision for income taxes adjusted for (1) restructuring and employee severance, (2) acquisition-related costs, (3) impairments and loss on disposal of assets, (4) litigation (recoveries)/charges, net and (5) Other Spin-Off Costs) divided by (earnings before income taxes and discontinued operations adjusted for the same five items). Non-GAAP Operating Earnings and growth rate calculation: operating earnings excluding (1) restructuring and employee severance, (2) acquisition-related costs, (3) impairments and loss on disposal of assets, (4) litigation (recoveries)/charges, net and (5) Other Spin-Off Costs.Non-GAAP Return on Equity: (annualized net earnings excluding (1) restructuring and employee severance, (2) acquisition-related costs, (3) impairments and loss on disposal of assets, (4) litigation (recoveries)/charges, net and (5) Other Spin-Off Costs, each net of tax) and divided by average shareholders' equity.Other Spin-Off Costs: costs incurred in connection with our Spin-Off of CareFusion which are included in distribution, selling, general and administrative expenses. Return on Equity: annualized net earnings divided by average shareholders' equity. Revenue Mix: segment revenue divided by total segment revenue for all segments. Segment Profit: segment revenue minus (segment cost of products sold and segment distribution, selling, general and administrative expenses). Segment Profit Margin: segment profit divided by segment revenue. Segment Profit Mix: segment profit divided by total segment profit for all segments.1     In this earnings release growth rates are determined by dividing the difference between current period results and prior period results by prior period results.2    Programs whereby the Company fundamentally changes its operations such as closing and consolidating facilities, moving manufacturing of a product to another location, production or business process sourcing, employee severance (including rationalizing headcount or other significant changes in personnel) and realigning operations (including substantial realignment of the management structure of a business unit in response to changing market conditions).3      Costs that consist primarily of transaction costs, integration costs, changes in the fair value of contingent consideration obligations and amortization of acquisition-related intangible assets.4      Asset impairments and losses from the disposal of assets not eligible to be classified as discontinued operations are classified within impairments and loss on disposal of assets within the condensed consolidated statements of earnings.5    Loss contingencies related to litigation and regulatory matters and income from favorable resolution of legal matters. SOURCE Cardinal HealthFor further information: Media: Debbie Mitchell, +1-614-757-6225, debbie.mitchell@cardinalhealth.com; Investors: Sally Curley, +1-614-757-7115, sally.curley@cardinalhealth.com